



# PHASE III CASPIAN TRIAL OF DURVALUMAB IN 1st LINE ES-SCLC

## PATIENTS

with previously untreated extensive-stage small cell lung cancer (ES-SCLC)

### During chemotherapy (EP)

**D+T+EP (carbo or cis)**  
4 cycles every 3 weeks

**D+EP (carbo or cis)**  
4 cycles every 3 weeks

**EP (carbo or cis)**  
Up to 6 cycles every 3 weeks

### Post-chemotherapy

**D** every 4 weeks until progression\*  
with 5<sup>th</sup> dose of **D+T** at week 16  
**No PCI allowed**

**D** every 4 weeks until progression\*  
**No PCI allowed**

**PCI**  
(optional)

### Primary endpoints

**OS**  
vs EP

**OS**  
vs EP

### Key Trial Characteristics

1

Control arm reflects real-world design with up to 6 cycles of EP and optional PCI

2

Flexibility of platinum-based regimens

\*or other discontinuation criteria are met

Early 2017

CASPIAN start date

Mid 2019

D + EP OS interim analysis (complete)

2020

Study Completion

**Key:** D: durvalumab T: tremelimumab Carbo: carboplatin Cis: cisplatin EP: etoposide plus investigator choice of cisplatin or carboplatin OS: overall survival PCI: prophylactic cranial irradiation

For use with healthcare-oriented media and patient advocacy groups only | US-32095 Last Updated 9/19

**References:** 1. ClinicalTrials.gov. Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN). Available at <https://clinicaltrials.gov/ct2/show/NCT03043872>. Accessed August 2019. 2. Fruh M, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(6):vi99–vi105.

